Alvaro Arjona-Sánchez, Francisco Javier Medina-Fernández, Francisco Cristobal Muñoz-Casares, Angela Casado-Adam, Juan Manuel Sánchez-Hidalgo, Sebastián Rufián-Peña, Unit of Oncological and Pancreatic Surgery, Department of General and Digestive Surgery, University Hospital Reina Sofia, 14004 Cordoba, Spain.
World J Gastrointest Oncol. 2014 Oct 15;6(10):407-12. doi: 10.4251/wjgo.v6.i10.407.
Colorectal peritoneal carcinomatosis was considered a terminal condition with a merely palliative treatment that included only supportive care, palliative surgery and the best systemic chemotherapy. Since the birth of a new approach, cytoreductive surgery with peritonectomy procedures together with hyperthermic intraperitoneal chemotherapy and/or early postoperative intraperitoneal chemotherapy to treat peritoneal carcinomatosis, many research groups contributed with promising results using this procedure being up to date this strategy the only one that has shown curative benefits on colorectal peritoneal carcinomatosis achieving reported overall survival rates up to 64 mo and five-year survival rates up to 51%. The aim of this paper is to expose an updated overview of the therapeutic possibilities of these procedures in colorectal peritoneal metastases in the same way that our Unit of Oncologic Surgery has performed since 1997 with more than four hundred procedures.
结直肠腹膜转移被认为是一种终末期疾病，只能进行姑息性治疗，包括支持性护理、姑息性手术和最佳全身化疗。自从一种新的治疗方法——细胞减灭术联合腹膜切除术和腹腔内热灌注化疗和/或术后早期腹腔内化疗治疗腹膜转移瘤诞生以来，许多研究小组都取得了有希望的结果，使用这种方法，到目前为止，这是唯一一种在结直肠腹膜转移瘤中显示出治愈益处的策略，报告的总生存率高达 64 个月，五年生存率高达 51%。本文旨在介绍这些方法在结直肠腹膜转移中的治疗可能性的最新概述，就像我们肿瘤外科自 1997 年以来进行的那样，已经进行了四百多次手术。
